John Coogan, EIR at Founders Fund, Founder of Soylent & Lucy

Company Origins and Founding Context

• John Coogan's previous company, Soylent, failed to secure funding for its original wireless mesh network idea due to high capital requirements and lack of traction.
• Soylent's pivot to a complete nutritional replacement drink originated from a viral blog post by co-founder Rob Rhinehart titled "How I Stopped Eating Food for 30 Days."
• The viral success led to a crowdfunding campaign where 10,000 people submitted detailed health data (23andMe, blood tests) within days, forcing a rapid product launch.
• Soylent reached $60 million in annual revenue but collapsed due to "bad team" dynamics and over-expansion before selling for a modest outcome.
• Coogan's current company, Lucy, was founded in 2016 as a response to the closing regulatory window for new nicotine products.
• Lucy was co-founded by a group including a biology major from Caltech who clarified that while nicotine is addictive, it is not a carcinogen.
• The founders leveraged previous DTC experience (shipping, Shopify, branding) to enter the nicotine replacement therapy (NRT) market before strict FDA regulations were fully enforced.

Regulatory Landscape and Market Strategy

• The FDA's regulatory framework for nicotine products, established via the 2009 Tobacco Control Act and Center for Tobacco Products, made 2016 the last viable year to launch new companies without a multi-year pre-market application.
• Launching new nicotine products now requires millions in upfront capital and a five-year wait for FDA approval, creating a high barrier similar to pharmaceutical development.
• The NRT market is currently under $1 billion in revenue, but the entry of competitors like Zyn has created significant growth drivers for pouch products.
• Lucy adopted a conservative, non-aggressive marketing strategy to avoid the youth initiation controversies that plagued Juul.
• The company distinguishes itself by avoiding TikTok advertising and targeting an older, middle-aged demographic ("dads") rather than youth culture.
• Coogan argues the current regulatory environment is inefficient, noting that the UK's National Health Service explicitly labeled Juul as 95% safer than cigarettes, while the US FDA has failed to issue similar definitive risk statements.
• The "Master Settlement Agreement" created a perverse incentive structure where tobacco companies pay fines that fund anti-smoking campaigns, while the industry remains profitable due to the addiction of legacy cigarette users.
• Coogan advocates for a "tilted playing field" where regulations and taxes on cigarettes are doubled compared to newer, less harmful nicotine products to accelerate the transition away from combustion.

Operational Challenges and Growth

• Lucy currently operates with a narrow product mix in the US market to avoid the exponential complexity of adding SKUs, channels, and international geographies simultaneously.
• The company recently right-sized its operations after canceling a fundraising round, achieving profitability by focusing on cash flow rather than vanity KPIs.
• Capital requirements for Lucy are front-loaded for regulatory compliance, after which the business functions as a working capital cycle (monthly revenue roughly equals inventory needs).
• Marketing relies on authentic user testimonials and direct outreach to retailers (e.g., convenience store owners) rather than broad consumer media campaigns.
• Unlike competitors Zyn and others, which were acquired by or owned by major tobacco giants (Altria, Philip Morris), Lucy positions itself as an independent challenger to Big Tobacco.

Industry Analysis: Juul, Vaping, and Public Perception

• Juul peaked at a $60 billion valuation before Altria invested $13 billion (30% stake), resulting in massive payouts for early employees and investors.
• The "Juul" brand became a verb and drove a massive decline in cigarette usage among adults but simultaneously triggered a youth vaping epidemic (rising from 10-20% to 30-40% usage).
• The E-Cigarette or Vaping Use-Associated Lung Injury (EVALI) crisis was caused by vitamin E acetate in black market THC vapes, not nicotine products, yet it devastated the entire e-cigarette sector's reputation.
• The FDA issued a Marketing Denial Order to Juul, though the company obtained a legal stay to continue selling while fighting the ban in court.
• Coogan disputes the "nicotine is a cognitive enhancer" narrative popular in tech circles, stating nicotine builds rapid tolerance and functions primarily as a mild stimulant similar to caffeine.
• Statistics cited: In the year of the pandemic, smoking caused more deaths (460,000) than COVID-19 (430,000) in the US.

Tech Trends and Founder Commentary

• Coogan criticizes the "hot take industrial complex" on social media, arguing that online discourse often focuses on trivial cultural wars (e.g., an Apple iPad ad) rather than substantive policy issues (e.g., the menthol cigarette ban).
• He suggests that the VC industry's de-prioritization of "lifestyle businesses" (companies making $1M–$10M annually) has stifled fun, low-risk entrepreneurship, preferring only massive power-law plays.
• Coogan identifies a gap in the AI market for "niche, consumer-facing gadgets" like the Rabbit R1, which he believes is well-suited for children as a "new age Tamagotchi" or educational tool.
• He observes that 18-year-old entrepreneurs are successfully building profitable micro-SaaS businesses (e.g., a $100k/month "Tinder text helper" app) but are discouraged by VC culture from pursuing these paths.
• Coogan advises founders to log off social media platforms to avoid algorithmic exhaustion and to focus on building tangible products rather than curating online personas.
• He predicts that the most successful AI startups will likely be those that solve specific, niche problems rather than attempting to replace entire platforms like smartphones.